Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy

被引：0
|
作者：
Dellepiane, C. [1 ]
Coco, S. [1 ]
Dal Bello, M. G. [1 ]
Rossi, G. [1 ]
Rijavec, E. [2 ]
Biello, F. [3 ]
Tagliamento, M. [1 ]
Longo, L. [1 ]
Mora, M. [4 ]
Anselmi, G. [4 ]
Alama, A. [1 ]
Bennicelli, E. [1 ]
Grossi, F. [2 ]
Zullo, L. [1 ]
Beshiri, K. [1 ]
Bottini, A. [1 ]
Pronzato, P. [1 ]
Genova, C. [1 ]
机构：
[1] IRCCS Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy
[3] Azienda Osped Univ Maggiore Carita, Med Oncol Unit, Novara, Italy
[4] IRCCS Osped Policlin San Martino, Pathol Unit, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318P
引用
收藏
页码：S851 / S851
页数：1
相关论文
共 50 条
  • [21] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [22] Clinical implications of mixed response on prognosis of non-small cell lung cancer (NSCLC) patients treated with Immunotherapy
    Lee, Seyoung
    Um, Taegyu
    Lee, Jeeyeon
    Kim, Peter Haseok
    Yadav, Monica
    Chuchuca, Maria J.
    Chung, Liam Il-Young
    Chae, Young Kwang
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
  • [24] The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Zhang, Shuling
    Bai, Xueli
    Shan, Fengping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [25] Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC).
    Feng, Zheng
    Schlichting, Michael
    Helwig, Christoph
    Chand, Vikram K.
    Gelb, Arnold
    Jin, Hulin
    Grote, Hans Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
    Meniawy, Tarek M.
    Lake, Richard A.
    McDonnell, Alison M.
    Millward, Michael J.
    Nowak, Anna K.
    LUNG CANCER, 2016, 93 : 9 - 16
  • [27] Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
    Takeuchi, Masahiro
    Doi, Tomomitsu
    Obayashi, Kunie
    Hirai, Ayako
    Yoneda, Kazue
    Tanaka, Fumihiro
    Iwai, Yoshiko
    IMMUNOLOGY LETTERS, 2018, 196 : 155 - 160
  • [28] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [29] Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)
    Valcarcel Gonzalez, S.
    Diaz, P.
    Villanueva Palicio, N.
    Alvarez Fernandez, C.
    Contreras Toledo, D. C.
    Mihic Gongora, L.
    Rodriguez Gonzalez, A.
    Velasco Durantez, V.
    Solis Hernandez, M. D. P.
    Esteban Gonzalez, E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S569 - S570
  • [30] The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy
    Xu, Y.
    Zhu, L.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S615 - S615
12345